Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)
Bruce Neal,
Lei Si,
Maoyi Tian,
Yishu Liu,
Xinyi Zhang,
Yangfeng Wu,
Jie Yu,
Jixin Sun,
Thomas Lung,
Yi Zhao,
Paul Elliott,
Liping Huang,
Xiangxian Feng,
Bo Zhou,
Xuejun Yin,
Lijing Yan,
Ruijuan Zhang,
Zhixin Hao,
Jingpu Shi,
Jianxin Zhang,
Yuhong Zhang,
Zhifang Li,
Yan Yu,
Ka-Chun Li,
Nicole Li,
Darwin Labarthe
Affiliations
Bruce Neal
The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
Lei Si
Western Sydney University, Penrith South, New South Wales, Australia
Maoyi Tian
6School of Public Health, Harbin Medical University, Harbin, Heilongjiang, China
Yishu Liu
The George Institute for Global Health, Beijing, China
Xinyi Zhang
1 Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
Yangfeng Wu
Peking University First Hospital, Beijing, China
Jie Yu
1 Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Jixin Sun
Department of Non-communicable Disease Prevention and Control, Center for Disease Control of Hebei Province, Shijiazhuang, China
Thomas Lung
Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia
Yi Zhao
Imperial College London School of Medicine, London, UK
Paul Elliott
Imperial College London, London, UK
Liping Huang
5 Food Policy, The George Institute for Global Heath, Sydney, New South Wales, Australia
Xiangxian Feng
Changzhi Medical College, Changzhi, China
Bo Zhou
5 Sichuan Provincial Center for Mental Health, Sichuan Provincial People`s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
Xuejun Yin
The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
Lijing Yan
The George Institute for Global Health at Peking University Health Science Center, Beijing, China
Ruijuan Zhang
Xian Jiaotong University, Xi`an, Shaanxi, China
Zhixin Hao
The George Institute for Global Health at Peking University Health Science Center, Beijing, China
Jingpu Shi
Department of Evidence-based Medicine, First Hospital of China Medical University, Shenyang, China
Jianxin Zhang
General Practice Department, Peking University First Hospital, Beijing, China
Yuhong Zhang
Takeda Pharmaceuticals, Cambridge, MA, USA
Zhifang Li
School of Public Health, Changzhi Medical College, Changzhi, China
Yan Yu
School of Public Health, Xian Jiaotong University, Xian, China
Ka-Chun Li
The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
Nicole Li
George Clinical, Sydney, New South Wales, Australia
Darwin Labarthe
Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
Introduction Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. Reducing dietary salt consumption is a potentially cost-effective way to reduce blood pressure and the burden of CVD. To date, economic evidence has focused on sodium reduction in food industry or processed food with blood pressure as the primary outcome. This study protocol describes the planned within-trial economic evaluation of a low-sodium salt substitute intervention designed to reduce the risk of stroke in China.Methods and analyses The economic evaluation will be conducted alongside the Salt Substitute and Stroke Study: a 5-year large scale, cluster randomised controlled trial. The outcomes of interest are quality of life measured using the EuroQol-5-Dimensions and major adverse cardiovascular events. Costs will be estimated from a healthcare system perspective and will be sought from the routinely collected data available within the New Rural Cooperative Medical Scheme. Cost-effectiveness and cost-utility analyses will be conducted, resulting in the incremental cost-effectiveness ratio expressed as cost per cardiovascular event averted and cost per quality-adjusted life year gained, respectively.Ethics and dissemination The trial received ethics approval from the University of Sydney Ethics Committee (2013/888) and Peking University Institutional Review Board (IRB00001052-13069). Informed consent was obtained from each study participant. Findings of the economic evaluation will be published in a peer-reviewed journal and presented at international conferences.Trial registration number ClinicalTrials.gov Registry (NCT02092090).
